

**Clinical trial results:****AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF S-1 AND CISPLATIN COMPARED WITH 5-FU AND CISPLATIN IN PATIENTS WITH METASTATIC DIFFUSE GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY****Summary**

EudraCT number	2009-016019-39
Trial protocol	DE BE HU GB ES PT EE IT BG LT
Global end of trial date	15 August 2014

**Results information**

Result version number	v1 (current)
This version publication date	02 November 2020
First version publication date	02 November 2020
Summary attachment (see zip file)	2009-016019-39 - TPU-S-1303 Final CSR Summary (2009-016019-39 - TPU-S-1303 Final CSR Synopsis _23Jan2014.pdf)

**Trial information****Trial identification**

Sponsor protocol code	TPU-S1303
-----------------------	-----------

**Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT01285557
WHO universal trial number (UTN)	-

Notes:

**Sponsors**

Sponsor organisation name	Taiho Oncology, Inc.
Sponsor organisation address	202 Carnegie Center, Suite 100, Princeton, United States, 08540
Public contact	Takekazu Aoyama, Taiho Oncology, Inc., 1 6097505300, aoyama@taihopui.com
Scientific contact	Takekazu Aoyama, Taiho Oncology, Inc., 1 6097505300, aoyama@taihopui.com

Notes:

**Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

---

**Results analysis stage**

---

Analysis stage	Final
Date of interim/final analysis	23 January 2015
Is this the analysis of the primary completion data?	Yes
Primary completion date	07 March 2014
Global end of trial reached?	Yes
Global end of trial date	15 August 2014
Was the trial ended prematurely?	Yes

Notes:

---

**General information about the trial**

---

Main objective of the trial:

To compare the following endpoints for the S-1/cisplatin regimen (experimental arm) with the 5-FU/cisplatin regimen control arm) in patients with metastatic diffuse gastric cancer:

- overall survival (OS)

Protection of trial subjects:

This study was conducted and informed consent was obtained according to the ethical principles that have their origins in the Declaration of Helsinki and its amendments, and in accordance with Title 21 CFR 312.50 through 312.70, the International Conference on Harmonisation (ICH) Tripartite Guidelines for Good Clinical Practice, and local and national laws and regulations relevant to the use of investigational therapeutic agents.

Patients were monitored for safety from the time of signed informed consent form through 30 days after the last dose of study medication or until the start of new antitumor therapy, whichever was earlier. Adverse events were coded using the Medical Dictionary for Regulatory Activities Dictionary (MedDRA), Version 14.0, and were categorized by system organ class (SOC) and preferred term (PT). Treatment-related SAEs that occurred after the 30-day follow-up.

Patients were followed for survival status every 8 weeks until death or until 2 years after the last patient was randomized in the study. During follow-up, CT scans were performed every 8 weeks until the occurrence of radiologic progression or the start of a new antitumor therapy.

Background therapy: -

Evidence for comparator:

At the present time, there is no universally accepted standard regimen in the treatment of front-line metastatic gastric cancer. Fluoropyrimidine- and platinum-based chemotherapies, as a doublet or as the backbone of triplet therapy, have been standard regimens used in the treatment of metastatic gastric cancer over several decades. Despite multiple randomized studies and meta-analyses, the definitive superiority of anthracycline-based triplet therapy over standard fluoropyrimidine-platinum based regimens has not been established.

The control arm of this study employs a fluoropyrimidine-platinum regimen that is commonly used by community oncologists and has been accepted as a standard control regimen by regulatory authorities in both Europe and the United States: 5-FU 800 mg/m<sup>2</sup>/24 hours administered as a CIV on Days 1 through 5 following 80 mg/m<sup>2</sup> cisplatin administered IV as a 1- to 3-hour infusion on Day 1. This regimen is repeated every 21 days.

Actual start date of recruitment	14 April 2011
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 32
Country: Number of subjects enrolled	Mexico: 7
Country: Number of subjects enrolled	Argentina: 2
Country: Number of subjects enrolled	Brazil: 18
Country: Number of subjects enrolled	Croatia: 2
Country: Number of subjects enrolled	Ukraine: 117
Country: Number of subjects enrolled	Russian Federation: 71
Country: Number of subjects enrolled	Israel: 1
Country: Number of subjects enrolled	South Africa: 3
Country: Number of subjects enrolled	Poland: 5
Country: Number of subjects enrolled	Portugal: 2
Country: Number of subjects enrolled	Romania: 12
Country: Number of subjects enrolled	Spain: 35
Country: Number of subjects enrolled	United Kingdom: 5
Country: Number of subjects enrolled	Belgium: 1
Country: Number of subjects enrolled	Bulgaria: 7
Country: Number of subjects enrolled	Estonia: 10
Country: Number of subjects enrolled	Germany: 3
Country: Number of subjects enrolled	Hungary: 9
Country: Number of subjects enrolled	Italy: 19
Worldwide total number of subjects	361
EEA total number of subjects	110

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	292
From 65 to 84 years	54
85 years and over	15

## Subject disposition

### Recruitment

Recruitment details:

The study enrolled male and female patients  $\geq 18$  years of age with histologically confirmed by Central Pathology Review, unresectable (at the time of screening for study eligibility), metastatic diffuse gastric cancer including carcinoma of the gastro-esophageal junction who had no prior chemotherapy for gastric cancer.

### Pre-assignment

Screening details:

All patients completed the following study procedures prior to a confirmation of eligibility: Signed ICF, Body Weight measurement, ECOG performance status, Infection Assessment, Histological Confirmation, Medical History, Audiogram, ECG, Chest X-ray (CXR), Tumor Measurements, Physical Exam, Vital Signs, Height, Baseline Signs & Symptoms and so on.

### Pre-assignment period milestones

Number of subjects started	690 <sup>[1]</sup>
Number of subjects completed	361

### Pre-assignment subject non-completion reasons

Reason: Number of subjects	Screen Failure: 329
----------------------------	---------------------

Notes:

[1] - The number of subjects reported to have started the pre-assignment period are not the same as the worldwide number enrolled in the trial. It is expected that these numbers will be the same.

Justification: 690 patients signed the ICF and started screening and out of 690 patients, 329 patients screened failed and therefore 361 patients were randomized

### Period 1

Period 1 title	Baseline Period
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Arm title	Baseline
-----------	----------

Arm description:

Baseline period; screening for eligibility in the study

Arm type	Baseline
Investigational medicinal product name	S-1
Investigational medicinal product code	L01BC53
Other name	Tegafur/gimeracil/oteracil
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

Dosage and administration details:

S-1 is an immediate release dosage form contained in hard gelatin capsules in which tegafur (FT), gimeracil (CDHP), and oteracil as monopotassium salt (Oxo) are combined at a molar ratio of 1:0.4:1. S-1 25 mg/m<sup>2</sup> was administered orally twice daily (BID) every 12 hours from Day 1 through Day 21 followed by a 7 day rest period on Days 22 to 28. This regimen was repeated every 28 days. S-1 was administered 1 hour before or 1 hour after a meal with a glass of water. Lot numbers were: 15-mg capsules, 0183, 2188, and 8G86; 20-mg capsules, 9E81, 1I91, and 13L8820.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	Cisplatinum, platamin, neoplatin, cismaplat, cis-diamminedichloridoplatinum(II) (CDDP)
Pharmaceutical forms	Solution for infusion

Routes of administration	Intravenous use
Dosage and administration details:	
Cisplatin used in the study was the commercially available product. Cisplatin 75 mg/m <sup>2</sup> was administered intravenously (IV) as a 1- to 3-hour infusion on Day 1 following the morning dose of S-1. This regimen was repeated every 28 days for a maximum of 8 cycles.	
Investigational medicinal product name	5-FU
Investigational medicinal product code	L01BC02
Other name	Fluorouracil
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:	
The 5-FU used in the study was the commercially available product. 5-FU 800 mg/m <sup>2</sup> /24 hours was administered intravenously (IV) by continuous infusion over 120 hours (on Days 1 through 5) followed by a 16-day rest period on Days 6 through 21. This regimen was repeated every 3 weeks.	
Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	Cisplatinum, platamin, neoplatin, cismaplat, cis-diamminedichloridoplatinum(II) (CDDP)
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Cisplatin used in the study was the commercially available product. Cisplatin 80 mg/m<sup>2</sup> was administered intravenously (IV) as a 1- to 3-hour infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles. This regimen was repeated every 21 days.

<b>Number of subjects in period 1</b>	Baseline
Started	361
Signed ICF	361
Body Weight	361
ECOG Performance Status	361
Infection Assessment	361
Histological Confirmation	361
Medical History	361
Audiogram	361
ECG	361
Chest X-ray (optional)	361
Tumor Measurements	361
Physical Exam	361
Vital Signs	361
Height	361
Baseline Signs & Symptoms	361
Hematology	361
Chemistry	361

Urinalysis	361
Pregnancy Test	361
International Normalized Ratio (INR)	361
Healthcare Utilization	361
AE/SAE Assessments	361
Concomitant Medications	361
Completed	361

## Period 2

Period 2 title	Treatment Period
Is this the baseline period?	No
Allocation method	Randomised - controlled
Blinding used	Not blinded

## Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	S-1/Cisplatin (experimental arm)

### Arm description:

Experimental arm, evaluating the efficacy and safety of the S-1/cisplatin regimen in chemotherapy-naïve patients with metastatic diffuse gastric cancer including carcinoma of the gastro-esophageal junction. Patients were stratified by: histologic subtype (adenocarcinoma, diffuse type or signet ring cell adenocarcinoma); extent of metastasis (1 versus more than 1 metastatic site); Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1); and Region (North America/Western Europe/Eastern Europe/Rest of World [ROW]).

Arm type	Experimental
Investigational medicinal product name	S-1
Investigational medicinal product code	L01BC53
Other name	Tegafur/gimeracil/oteracil
Pharmaceutical forms	Capsule, hard
Routes of administration	Oral use

### Dosage and administration details:

S-1 is an immediate release dosage form contained in hard gelatin capsules in which tegafur (FT), gimeracil (CDHP), and oteracil as monopotassium salt (Oxo) are combined at a molar ratio of 1:0.4:1. S-1 25 mg/m<sup>2</sup> was administered orally twice daily (BID) every 12 hours from Day 1 through Day 21 followed by a 7 day rest period on Days 22 to 28. This regimen was repeated every 28 days. S-1 was administered 1 hour before or 1 hour after a meal with a glass of water. Lot numbers were: 15-mg capsules, 0183, 2188, and 8G86; 20-mg capsules, 9E81, 1I91, and 13L8820.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	Cisplatinum, platamin, neoplatin, cismaplat, cis-diamminedichloridoplatinum(II) (CDDP)
Pharmaceutical forms	Solution for infusion
Routes of administration	Intravenous use

### Dosage and administration details:

Cisplatin used in the study was the commercially available product. Cisplatin 75 mg/m<sup>2</sup> was administered intravenously (IV) as a 1- to 3-hour infusion on Day 1 following the morning dose of S-1. This regimen was repeated every 28 days for a maximum of 8 cycles.

<b>Arm title</b>	5-FU/Cisplatin (control arm)
------------------	------------------------------

Arm description:

Control arm, evaluating the efficacy and safety of 5-FU/Cisplatin regimen in chemotherapy-naïve patients with metastatic diffuse gastric carcinoma including carcinoma of the gastro-esophageal junction. Patients were stratified by: histologic subtype (adenocarcinoma, diffuse type or signet ring cell adenocarcinoma); extent of metastasis (1 versus more than 1 metastatic site); Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1); and Region (North America/Western Europe/Eastern Europe/Rest of World [ROW]).

Arm type	Active comparator
Investigational medicinal product name	5-FU
Investigational medicinal product code	L01BC02
Other name	Fluorouracil
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

The 5-FU used in the study was the commercially available product. 5-FU 800 mg/m<sup>2</sup>/24 hours was administered intravenously (IV) by continuous infusion over 120 hours (on Days 1 through 5) followed by a 16-day rest period on Days 6 through 21. This regimen was repeated every 3 weeks.

Investigational medicinal product name	Cisplatin
Investigational medicinal product code	
Other name	Cisplatinum, platamin, neoplatin, cismaplat, cis-diamminedichloridoplatinum(II) (CDDP)
Pharmaceutical forms	Solution for injection
Routes of administration	Intravenous use

Dosage and administration details:

Cisplatin used in the study was the commercially available product. Cisplatin 80 mg/m<sup>2</sup> was administered intravenously (IV) as a 1- to 3-hour infusion on Day 1 prior to the start of the 5-FU infusion on Day 1 for a maximum of 8 cycles. This regimen was repeated every 21 days.

<b>Number of subjects in period 2</b>	S-1/Cisplatin (experimental arm)	5-FU/Cisplatin (control arm)
Started	239	122
Randomization	239	122
Body Weight	239	122
ECOG Performance Status	239	122
Audiogram	239	122
Chest X-ray (CXR)	239	122
Tumor Assessments	239	122
Physical Exam	239	122
Vital Signs	239	122
Hematology	239	122
Chemistry	239	122
Urinalysis	239	122
INR	239	122
Arm A (S-1) or Arm B (5-FU) treatment	238	121
Hydration	239	122

Healthcare Utilization	239	122
AE/SAE Assessments	239	122
Concomitant Medications	239	122
Completed	238	121
Not completed	1	1
Randomized but not Treated	1	1

### Period 3

Period 3 title	End of Treatment Period
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	S-1/Cisplatin (experimental arm)
Arm description: -	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
<b>Arm title</b>	5-FU/Cisplatin (control arm)
Arm description: -	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

<b>Number of subjects in period 3</b>	S-1/Cisplatin (experimental arm)	5-FU/Cisplatin (control arm)
Started	238	121
Body Weight	238	121
ECOG Performance Status	238	121
Audiogram	238	121
Chest X-Ray (CXR) (optional)	238	121
Tumor Assessments	238	121
Physical Exam	238	121
Vital Signs	238	121
Hematology	238	121
Chemistry	238	121
Urinalysis	238	121
INR	238	121
Healthcare Utilization	238	121

AE/SAE Assessments	238	121
Concomitant Medications	238	121
Survival follow-up	238	121
Completed	19	10
Not completed	219	111
Consent withdrawn by subject	14	13
Physician decision	4	2
Adverse event, non-fatal	22	10
Clinical disease progression	46	23
Lost to follow-up	2	4
Radiologic progression	127	59
Protocol deviation	4	-

## Baseline characteristics

### Reporting groups

Reporting group title	Baseline
-----------------------	----------

Reporting group description:

Baseline period; screening for eligibility in the study

Reporting group values	Baseline	Total	
Number of subjects	361	361	
Age categorical			
Units: Subjects			
Adults (18-64 years)	292	292	
From 65-84 years	69	69	
Age continuous			
Units: years			
median	55.4		
standard deviation	± 11.27	-	
Gender categorical			
Units: Subjects			
Female	177	177	
Male	184	184	
Race			
Units: Subjects			
Caucasian/White	343	343	
Black	6	6	
Asian/Oriental	4	4	
American Indian or Alaska Native	2	2	
Other	6	6	
Ethnicity			
Units: Subjects			
Hispanic or Latino	39	39	
Not Hispanic or Latino	321	321	
Not Collected	1	1	
Weight			
Units: kg			
arithmetic mean	67.6		
standard deviation	± 15.44	-	
Height			
Units: cm			
arithmetic mean	166.5		
standard deviation	± 9.13	-	
Body Surface Area (BSA)			
Units: m2			
arithmetic mean	1.749		
standard deviation	± 0.2062	-	

## Subject analysis sets

Subject analysis set title	Intention to treat (ITT)
Subject analysis set type	Intention-to-treat
Subject analysis set description: ITT population - Total patients who were randomized	
Subject analysis set title	Intention to treat (ITT) - S-1/Cisplatin
Subject analysis set type	Intention-to-treat
Subject analysis set description: Intention to treat (ITT) population in the S-1/Cisplatin experimental group	
Subject analysis set title	Intention to treat (ITT) - 5-FU/Cisplatin
Subject analysis set type	Intention-to-treat
Subject analysis set description: Intention to treat (ITT) population in the 5-FU/Cisplatin control group	

Reporting group values	Intention to treat (ITT)	Intention to treat (ITT) - S-1/Cisplatin	Intention to treat (ITT) - 5-FU/Cisplatin
Number of subjects	361	239	122
Age categorical Units: Subjects			
Adults (18-64 years)	292	199	93
From 65-84 years	69	40	29
Age continuous Units: years			
median	55.4	55.1	55.8
standard deviation	± 11.27	± 11.01	± 11.80
Gender categorical Units: Subjects			
Female	177	115	62
Male	184	124	60
Race Units: Subjects			
Caucasian/White	343	226	117
Black	6	4	2
Asian/Oriental	4	4	0
American Indian or Alaska Native	2	2	0
Other	6	3	3
Ethnicity Units: Subjects			
Hispanic or Latino	39	26	13
Not Hispanic or Latino	321	213	108
Not Collected	1	0	1
Weight Units: kg			
arithmetic mean	67.6	67.5	67.7
standard deviation	± 15.44	± 16.16	± 13.98
Height Units: cm			
arithmetic mean	166.5	166.4	166.8
standard deviation	± 9.13	± 9.53	± 8.31
Body Surface Area (BSA) Units: m2			

arithmetic mean	1.749	1.746	1.754
standard deviation	± 0.2062	± 0.2147	± 0.1889

---

---

## End points

### End points reporting groups

Reporting group title	Baseline
-----------------------	----------

Reporting group description:

Baseline period; screening for eligibility in the study

Reporting group title	S-1/Cisplatin (experimental arm)
-----------------------	----------------------------------

Reporting group description:

Experimental arm, evaluating the efficacy and safety of the S-1/cisplatin regimen in chemotherapy-naïve patients with metastatic diffuse gastric cancer including carcinoma of the gastro-esophageal junction. Patients were stratified by: histologic subtype (adenocarcinoma, diffuse type or signet ring cell adenocarcinoma); extent of metastasis (1 versus more than 1 metastatic site); Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1); and Region (North America/Western Europe/Eastern Europe/Rest of World [ROW]).

Reporting group title	5-FU/Cisplatin (control arm)
-----------------------	------------------------------

Reporting group description:

Control arm, evaluating the efficacy and safety of 5-FU/Cisplatin regimen in chemotherapy-naïve patients with metastatic diffuse gastric carcinoma including carcinoma of the gastro-esophageal junction. Patients were stratified by: histologic subtype (adenocarcinoma, diffuse type or signet ring cell adenocarcinoma); extent of metastasis (1 versus more than 1 metastatic site); Eastern Cooperative Oncology Group (ECOG) performance status (0 or 1); and Region (North America/Western Europe/Eastern Europe/Rest of World [ROW]).

Reporting group title	S-1/Cisplatin (experimental arm)
-----------------------	----------------------------------

Reporting group description: -

Reporting group title	5-FU/Cisplatin (control arm)
-----------------------	------------------------------

Reporting group description: -

Subject analysis set title	Intention to treat (ITT)
----------------------------	--------------------------

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

ITT population - Total patients who were randomized

Subject analysis set title	Intention to treat (ITT) - S-1/Cisplatin
----------------------------	--

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

Intention to treat (ITT) population in the S-1/Cisplatin experimental group

Subject analysis set title	Intention to treat (ITT) - 5-FU/Cisplatin
----------------------------	---

Subject analysis set type	Intention-to-treat
---------------------------	--------------------

Subject analysis set description:

Intention to treat (ITT) population in the 5-FU/Cisplatin control group

### Primary: Overall Survival (OS)

End point title	Overall Survival (OS)
-----------------	-----------------------

End point description:

Overall Survival (OS) was the primary endpoint of this study and was defined as the time from the day of randomization to the date of death for the Intent-to-treat (ITT) population. Patients who did not die as of the OS cut-off date were censored at the date last known to be alive. The difference in OS between the 2 treatment groups was assessed using the unstratified log-rank test (Score statistic from PHREG and ties=Breslow). Survival for each group was summarized using Kaplan Meier curves and was further characterized in terms of the median and survival probability at 3, 6, 9 and 12 months, along with the corresponding 2-sided 95% confidence intervals for the estimates. Confidence intervals (CIs) for median survival were based upon the methods of Brookmeyer and Crowley. The influence of stratification factors and other baseline characteristics was assessed using the stratified log-rank test and Cox's regression approach.

End point type	Primary
----------------	---------

End point timeframe:

The time from randomization to the date of death for the Intent-to-treat (ITT) population.

<b>End point values</b>	S-1/Cisplatin (experimental arm)	5-FU/Cisplatin (control arm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	239	122		
Units: months				
median (confidence interval 95%)	7.5 (6.7 to 9.3)	6.6 (5.7 to 8.1)		

## Statistical analyses

<b>Statistical analysis title</b>	Overall survival (OS)
-----------------------------------	-----------------------

Statistical analysis description:

The difference in OS between the 2 treatment groups was assessed using the unstratified log-rank test (Score statistic from PHREG and ties=Breslow). Survival for each group was summarized using Kaplan Meier curves and was further characterized in terms of the median and survival probability at 3, 6, 9 and 12 months, along with the corresponding 2-sided 95% confidence intervals for the estimates.

Confidence intervals (CIs) for median survival

were based upon the methods of Brookmeyer and Crowley

Comparison groups	S-1/Cisplatin (experimental arm) v 5-FU/Cisplatin (control arm)
Number of subjects included in analysis	361
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.9312
Method	t-test, 2-sided
Parameter estimate	Hazard ratio (HR)
Point estimate	0.99
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.76
upper limit	1.28
Variability estimate	Standard deviation

## Secondary: Progression-free survival (PFS)

End point title	Progression-free survival (PFS)
-----------------	---------------------------------

End point description:

Progression-free survival was defined as the time from date of randomization until date of radiological disease progression or death due to any cause. Patients who were alive with no disease progression were censored at the date of the last tumor assessment. Patients who received new anticancer therapy before disease progression were censored at the date of the last evaluable tumor assessment before new anticancer therapy was initiated.

End point type	Secondary
----------------	-----------

End point timeframe:

Progression-free survival was defined as the time from date of randomization until date of radiological disease progression or death due to any cause.

<b>End point values</b>	S-1/Cisplatin (experimental arm)	5-FU/Cisplatin (control arm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	239	122		
Units: months				
median (confidence interval 95%)	4.4 (3.8 to 5.6)	3.9 (3.6 to 5.2)		

## Statistical analyses

<b>Statistical analysis title</b>	Progression-Free Survival (months)
Statistical analysis description:	
Progression-Free Survival (PFS) were analyzed using the same methods as for the primary endpoint - Overall Survival (OS).	
Comparison groups	S-1/Cisplatin (experimental arm) v 5-FU/Cisplatin (control arm)
Number of subjects included in analysis	361
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.3039
Method	t-test, 2-sided
Parameter estimate	Hazard ratio (HR)
Point estimate	0.86
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.65
upper limit	1.14
Variability estimate	Standard deviation

## Secondary: Time to treatment failure (TTF)

<b>End point title</b>	Time to treatment failure (TTF)
End point description:	
Time to treatment failure was defined as the time from date of randomization until date of disease progression (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause. Patients who were still on study treatment at the time of the analysis were censored at the last date the patient was known to be on treatment.	
End point type	Secondary
End point timeframe:	
Time to treatment failure was defined as the time from date of randomization until date of disease progression (clinical or radiologic), or permanent discontinuation of study treatment (S-1 or 5-FU), or death due to any cause.	

<b>End point values</b>	S-1/Cisplatin (experimental arm)	5-FU/Cisplatin (control arm)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	239	122		
Units: months				
median (confidence interval 95%)	4.2 (3.8 to 4.9)	3.8 (3.4 to 4.3)		

## Statistical analyses

<b>Statistical analysis title</b>	Time to treatment failure (TTF)
Statistical analysis description:	
Time to treatment failure (TTF) was analyzed using the same methods as for the primary endpoint Overall Survival (OS).	
Comparison groups	S-1/Cisplatin (experimental arm) v 5-FU/Cisplatin (control arm)
Number of subjects included in analysis	361
Analysis specification	Pre-specified
Analysis type	equivalence
P-value	= 0.1683
Method	t-test, 2-sided
Parameter estimate	Hazard ratio (HR)
Point estimate	0.84
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.66
upper limit	1.08
Variability estimate	Standard deviation

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

Patients were monitored for safety from the time of signed informed consent form through 30 days after the last dose of study medication or until the start of new antitumor therapy, whichever was earlier.

Adverse event reporting additional description:

Adverse events were coded using the Medical Dictionary for Regulatory Activities Dictionary (MedDRA), Version 14.0, and were categorized by system organ class (SOC) and preferred term (PT).

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	14
--------------------	----

### Reporting groups

Reporting group title	S-1/Cisplatin (As Treated Population)
-----------------------	---------------------------------------

Reporting group description:

Adverse Events occurring in subjects within the S-1/Cisplatin group (As Treated Population)

Reporting group title	5-FU/Cisplatin (As Treated Population)
-----------------------	--

Reporting group description:

Adverse Events occurring in subjects within the 5-FU/Cisplatin group (As Treated Population)

<b>Serious adverse events</b>	S-1/Cisplatin (As Treated Population)	5-FU/Cisplatin (As Treated Population)	
Total subjects affected by serious adverse events			
subjects affected / exposed	63 / 230 (27.39%)	31 / 118 (26.27%)	
number of deaths (all causes)	169	89	
number of deaths resulting from adverse events	17	5	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Paraneoplastic Syndrome			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Vascular disorders			
Deep vein thrombosis			
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypovolaemic shock			

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pulmonary Embolism</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>General disorders and administration site conditions</b>			
<b>Asthenia</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Death</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Disease progression</b>			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
<b>Device Dislocation</b>			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Device Occlusion</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>General Physical Health Deterioration</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Infusion Site Extravasation</b>			

subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Mucosal Inflammation</b>			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pyrexia</b>			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Systemic inflammatory response syndrome</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Respiratory, thoracic and mediastinal disorders</b>			
<b>Pleural Effusion</b>			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pulmonary Artery Thrombosis</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pulmonary Embolism</b>			
subjects affected / exposed	2 / 230 (0.87%)	2 / 118 (1.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Psychiatric disorders</b>			
<b>Confusional State</b>			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Investigations			
Blood Creatinine Increased			
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 3	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutrophil Count Decreased			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Platelet Count Decreased			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Overdose			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Spinal Fracture			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity To Various Agents			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Cardiac disorders			
Acute Coronary Syndrome			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Acute myocardial infarction			

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cytotoxic Cardiomyopathy</b>			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
<b>Nervous system disorders</b>			
<b>Aphasia</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cerebral Haemorrhage</b>			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
<b>Convulsion</b>			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Dizziness</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Extrapyramidal Disorder</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Ischaemic Stroke</b>			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Parkinson's Disease</b>			

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Syncope			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Blood and lymphatic system disorders			
Anaemia			
subjects affected / exposed	11 / 230 (4.78%)	5 / 118 (4.24%)	
occurrences causally related to treatment / all	0 / 12	0 / 5	
deaths causally related to treatment / all	0 / 0	0 / 0	
Febrile Neutropenia			
subjects affected / exposed	0 / 230 (0.00%)	2 / 118 (1.69%)	
occurrences causally related to treatment / all	0 / 0	0 / 3	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenia			
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pancytopenia			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Thrombocytopenia			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ear and labyrinth disorders			
Vertigo positional			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal disorders			

Abdominal Distension			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Pain			
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Abdominal Pain Upper			
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Ascites			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Diarrhoea			
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dysphagia			
subjects affected / exposed	4 / 230 (1.74%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastric haemorrhage			
subjects affected / exposed	3 / 230 (1.30%)	4 / 118 (3.39%)	
occurrences causally related to treatment / all	0 / 3	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 1	
Gastric Perforation			
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 1	0 / 1	
Gastric Stenosis			

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Gastrointestinal haemorrhage</b>		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 2	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
<b>Gastrointestinal Obstruction</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Haematemesis</b>		
subjects affected / exposed	1 / 230 (0.43%)	2 / 118 (1.69%)
occurrences causally related to treatment / all	0 / 1	0 / 2
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Haemorrhoids</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Intestinal Obstruction</b>		
subjects affected / exposed	3 / 230 (1.30%)	2 / 118 (1.69%)
occurrences causally related to treatment / all	0 / 5	0 / 3
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Large Intestinal Obstruction</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 1	0 / 0
<b>Melaena</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0
<b>Nausea</b>		

subjects affected / exposed	4 / 230 (1.74%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 4	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Obstruction Gastric</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Pancreatitis Acute</b>			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Upper gastrointestinal haemorrhage</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
<b>Vomiting</b>			
subjects affected / exposed	5 / 230 (2.17%)	4 / 118 (3.39%)	
occurrences causally related to treatment / all	0 / 5	0 / 4	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Hepatobiliary disorders</b>			
<b>Biliary Colic</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Cholecystitis Acute</b>			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Jaundice Cholestatic</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Bronchopneumonia</b>			

subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Enterocolitis Infectious</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Renal and urinary disorders</b>			
<b>Renal Failure Acute</b>			
subjects affected / exposed	5 / 230 (2.17%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 5	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Ureteric Obstruction</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Urinary Tract Obstruction</b>			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Musculoskeletal and connective tissue disorders</b>			
<b>Back Pain</b>			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 2	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Infections and infestations</b>			
<b>Abdominal Infection</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
<b>Biliary Tract Infection</b>			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Infection			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung Infection			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neutropenic Sepsis			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Pneumonia			
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 3	0 / 0	
deaths causally related to treatment / all	0 / 2	0 / 0	
Pyelonephritis Acute			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Sepsis			
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 2	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 1	
Septic Shock			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 1	0 / 0	
Upper Respiratory Tract Infection			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Metabolism and nutrition disorders			

Decreased Appetite			
subjects affected / exposed	3 / 230 (1.30%)	2 / 118 (1.69%)	
occurrences causally related to treatment / all	0 / 2	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	
Dehydration			
subjects affected / exposed	6 / 230 (2.61%)	4 / 118 (3.39%)	
occurrences causally related to treatment / all	0 / 6	0 / 4	
deaths causally related to treatment / all	0 / 1	0 / 0	
Hypocalcaemia			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypokalaemia			
subjects affected / exposed	0 / 230 (0.00%)	4 / 118 (3.39%)	
occurrences causally related to treatment / all	0 / 0	0 / 6	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hypomagnesaemia			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Hyponatraemia			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	S-1/Cisplatin (As Treated Population)	5-FU/Cisplatin (As Treated Population)	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	214 / 230 (93.04%)	111 / 118 (94.07%)	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Fibroma			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	

Malignant Ascites			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Papilloma			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Paraneoplastic Syndrome			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Vascular disorders			
Aortic Aneurysm			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Capillary Fragility			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Deep Vein Thrombosis			
subjects affected / exposed	11 / 230 (4.78%)	3 / 118 (2.54%)	
occurrences (all)	12	3	
Dizziness			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Embolism			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Flushing			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Haematoma			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Hot Flush			
subjects affected / exposed	2 / 230 (0.87%)	2 / 118 (1.69%)	
occurrences (all)	2	2	
Hyperaemia			

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hypertension		
subjects affected / exposed	3 / 230 (1.30%)	2 / 118 (1.69%)
occurrences (all)	4	3
Hypertensive Crisis		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Hypotension		
subjects affected / exposed	2 / 230 (0.87%)	4 / 118 (3.39%)
occurrences (all)	3	4
Hypovolaemic Shock		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Lymphoedema		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Orthostatic Hypotension		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Pallor		
subjects affected / exposed	4 / 230 (1.74%)	0 / 118 (0.00%)
occurrences (all)	4	0
Pelvic Venous Thrombosis		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Peripheral Coldness		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Petechiae		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Phlebitis		
subjects affected / exposed	2 / 230 (0.87%)	3 / 118 (2.54%)
occurrences (all)	2	4
Pulmonary Embolism		

subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Subclavian Vein Thrombosis subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Thrombosis subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Venous Valve Ruptured subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
General disorders and administration site conditions			
Administration Site Pain subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Application Site Pain subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	0 / 118 (0.00%) 0	
Application Site Reaction subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Asthenia subjects affected / exposed occurrences (all)	56 / 230 (24.35%) 81	36 / 118 (30.51%) 61	
Catheter Site Haemorrhage subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Catheter Site Pain subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Catheter Site Phlebitis subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Catheter Site Pruritus			

subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Catheter Site Rash		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Chest Discomfort		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Chest Pain		
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)
occurrences (all)	4	1
Chills		
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)
occurrences (all)	3	0
Death		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Device Dislocation		
subjects affected / exposed	0 / 230 (0.00%)	2 / 118 (1.69%)
occurrences (all)	0	2
Device Occlusion		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Disease Progression		
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)
occurrences (all)	3	1
Early Satiety		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Facial Pain		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Fatigue		
subjects affected / exposed	59 / 230 (25.65%)	28 / 118 (23.73%)
occurrences (all)	104	51
Feeling Cold		

subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
General Physical Health Deterioration		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Generalised Oedema		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hyperthermia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Implant Site Discharge		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Infusion Site Extravasation		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Infusion Site Swelling		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Injection Site Erythema		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Injection Site Swelling		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Local Swelling		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Localised Oedema		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Malaise		
subjects affected / exposed	5 / 230 (2.17%)	1 / 118 (0.85%)
occurrences (all)	6	1
Mucosal Dryness		

subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
<b>Mucosal Inflammation</b>		
subjects affected / exposed	20 / 230 (8.70%)	20 / 118 (16.95%)
occurrences (all)	24	37
<b>Nodule</b>		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
<b>Non-Cardiac Chest Pain</b>		
subjects affected / exposed	5 / 230 (2.17%)	0 / 118 (0.00%)
occurrences (all)	6	0
<b>Oedema</b>		
subjects affected / exposed	1 / 230 (0.43%)	2 / 118 (1.69%)
occurrences (all)	1	2
<b>Oedema Peripheral</b>		
subjects affected / exposed	17 / 230 (7.39%)	7 / 118 (5.93%)
occurrences (all)	20	9
<b>Pain</b>		
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)
occurrences (all)	3	1
<b>Pyrexia</b>		
subjects affected / exposed	19 / 230 (8.26%)	7 / 118 (5.93%)
occurrences (all)	28	9
<b>Suprapubic Pain</b>		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
<b>Systemic Inflammatory Response Syndrome</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Temperature Intolerance</b>		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
<b>Xerosis</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0

Biliary Colic subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Cholangitis subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Cholecystitis subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Immune system disorders Contrast Media Allergy subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Drug Hypersensitivity subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Hypersensitivity subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	1 / 118 (0.85%) 1	
Seasonal Allergy subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Reproductive system and breast disorders Metrorrhagia subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Pelvic Pain subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	0 / 118 (0.00%) 0	
Retracted Nipple subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Vulvovaginal Pain subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders			

Acute Respiratory Failure		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Atelectasis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Bronchospasm		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Chronic Obstructive Pulmonary Disease		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Cough		
subjects affected / exposed	15 / 230 (6.52%)	5 / 118 (4.24%)
occurrences (all)	19	5
Dysphonia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Dyspnoea		
subjects affected / exposed	19 / 230 (8.26%)	8 / 118 (6.78%)
occurrences (all)	26	13
Epistaxis		
subjects affected / exposed	4 / 230 (1.74%)	1 / 118 (0.85%)
occurrences (all)	5	1
Hiccups		
subjects affected / exposed	9 / 230 (3.91%)	0 / 118 (0.00%)
occurrences (all)	12	0
Hydrothorax		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hypoventilation		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hypoxia		

subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Nasal Discomfort		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Nasal Dryness		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Nasal Inflammation		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Oropharyngeal Pain		
subjects affected / exposed	9 / 230 (3.91%)	2 / 118 (1.69%)
occurrences (all)	11	2
Pleural Effusion		
subjects affected / exposed	4 / 230 (1.74%)	2 / 118 (1.69%)
occurrences (all)	4	2
Pleurisy		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Pleuritic Pain		
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)
occurrences (all)	4	0
Pneumonitis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Productive Cough		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Pulmonary Artery Thrombosis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Pulmonary Embolism		
subjects affected / exposed	7 / 230 (3.04%)	3 / 118 (2.54%)
occurrences (all)	8	3
Pulmonary Infarction		

subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Respiratory Distress subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Respiratory Tract Congestion subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Rhinitis Allergic subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	1 / 118 (0.85%) 1	
Rhinorrhoea subjects affected / exposed occurrences (all)	3 / 230 (1.30%) 3	1 / 118 (0.85%) 1	
Sinus Congestion subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 3	0 / 118 (0.00%) 0	
Palmar-Plantar Erythrodysesthesia Syndrome subjects affected / exposed occurrences (all)	4 / 230 (1.74%) 7	1 / 118 (0.85%) 1	
Psychiatric disorders			
Anxiety subjects affected / exposed occurrences (all)	6 / 230 (2.61%) 7	2 / 118 (1.69%) 8	
Bradyphrenia subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Confusional State subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	1 / 118 (0.85%) 1	
Depression subjects affected / exposed occurrences (all)	6 / 230 (2.61%) 6	0 / 118 (0.00%) 0	
Disorientation			

subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Insomnia			
subjects affected / exposed occurrences (all)	13 / 230 (5.65%) 14	5 / 118 (4.24%) 5	
Mental Status Changes			
subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	0 / 118 (0.00%) 0	
Panic Attack			
subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Restlessness			
subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Stress			
subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Investigations			
Alanine Aminotransferase Increased subjects affected / exposed occurrences (all)	9 / 230 (3.91%) 11	4 / 118 (3.39%) 4	
Aspartate Aminotransferase Increased subjects affected / exposed occurrences (all)	12 / 230 (5.22%) 13	4 / 118 (3.39%) 4	
Bilirubin Conjugated Increased subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Blood Alkaline Phosphatase Increased subjects affected / exposed occurrences (all)	9 / 230 (3.91%) 10	1 / 118 (0.85%) 1	
Blood Amylase Increased subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 2	0 / 118 (0.00%) 0	
Blood Bilirubin Increased			

subjects affected / exposed	13 / 230 (5.65%)	1 / 118 (0.85%)
occurrences (all)	17	1
Blood Chloride Decreased		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Blood Creatinine Increased		
subjects affected / exposed	23 / 230 (10.00%)	9 / 118 (7.63%)
occurrences (all)	29	12
Blood Lactate Dehydrogenase Increased		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Blood Potassium Increased		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	2	1
Blood Pressure Increased		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Blood Urea Increased		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Body Temperature Increased		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Breath Sounds Abnormal		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Creatinine Renal Clearance Decreased		
subjects affected / exposed	9 / 230 (3.91%)	8 / 118 (6.78%)
occurrences (all)	9	10
Eastern Cooperative Oncology Group Performance Status Worsened		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Gamma-Glutamyltransferase Increased		

subjects affected / exposed occurrences (all)	3 / 230 (1.30%) 3	2 / 118 (1.69%) 2
Haemoglobin Decreased subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	2 / 118 (1.69%) 2
Hepatic Enzyme Increased subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0
Lipase Increased subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0
Liver Function Test Abnormal subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0
Lymph Node Palpable subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	0 / 118 (0.00%) 0
Lymphocyte Count Decreased subjects affected / exposed occurrences (all)	4 / 230 (1.74%) 5	2 / 118 (1.69%) 4
Neutrophil Count Decreased subjects affected / exposed occurrences (all)	4 / 230 (1.74%) 13	3 / 118 (2.54%) 6
Platelet Count Decreased subjects affected / exposed occurrences (all)	4 / 230 (1.74%) 7	2 / 118 (1.69%) 7
Transaminases Increased subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1
Tumour Marker Increased subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0
Weight Decreased subjects affected / exposed occurrences (all)	40 / 230 (17.39%) 42	18 / 118 (15.25%) 18
Weight Increased		

subjects affected / exposed occurrences (all)	3 / 230 (1.30%) 3	1 / 118 (0.85%) 1	
White Blood Cell Count Decreased subjects affected / exposed occurrences (all)	9 / 230 (3.91%) 21	3 / 118 (2.54%) 5	
White Blood Cells Semen Positive subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Injury, poisoning and procedural complications			
Contusion subjects affected / exposed occurrences (all)	3 / 230 (1.30%) 3	1 / 118 (0.85%) 1	
Expired Drug Administered subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	0 / 118 (0.00%) 0	
Fall subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Incision Site Erythema subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Incision Site Pain subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	0 / 118 (0.00%) 0	
Laceration subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	2 / 118 (1.69%) 2	
Overdose subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Pneumonitis Chemical subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Procedural Pain			

subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Procedural Site Reaction subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Seroma subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Spinal Fracture subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Thermal Burn subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Toxicity To Various Agents subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Cardiac disorders			
Acute Coronary Syndrome subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Acute Myocardial Infarction subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Angina Pectoris subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Bradycardia subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Cardiac Failure subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Cytotoxic Cardiomyopathy subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	

Intracardiac Thrombus			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Palpitations			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Sinus Bradycardia			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Tachycardia			
subjects affected / exposed	2 / 230 (0.87%)	2 / 118 (1.69%)	
occurrences (all)	2	2	
<b>Nervous system disorders</b>			
Acoustic Neuritis			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Amnesia			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Aphasia			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Balance Disorder			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Cerebral Haemorrhage			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Cerebral Infarction			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Cervical Root Pain			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Convulsion			

subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Dizziness		
subjects affected / exposed	16 / 230 (6.96%)	6 / 118 (5.08%)
occurrences (all)	33	9
Dysaesthesia		
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)
occurrences (all)	4	0
Dysgeusia		
subjects affected / exposed	11 / 230 (4.78%)	5 / 118 (4.24%)
occurrences (all)	12	7
Dyskinesia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Extrapyramidal Disorder		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Headache		
subjects affected / exposed	18 / 230 (7.83%)	7 / 118 (5.93%)
occurrences (all)	32	7
Hemiplegia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hypersomnia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hypoaesthesia		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
Ischaemic Stroke		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Lethargy		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Loss Of Consciousness		

subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Neuralgia		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
Neuropathy Peripheral		
subjects affected / exposed	23 / 230 (10.00%)	14 / 118 (11.86%)
occurrences (all)	28	17
Neurotoxicity		
subjects affected / exposed	4 / 230 (1.74%)	1 / 118 (0.85%)
occurrences (all)	8	2
Paraesthesia		
subjects affected / exposed	2 / 230 (0.87%)	2 / 118 (1.69%)
occurrences (all)	2	2
Paraparesis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Parkinson's Disease		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Peripheral Motor Neuropathy		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
Peripheral Sensory Neuropathy		
subjects affected / exposed	6 / 230 (2.61%)	1 / 118 (0.85%)
occurrences (all)	6	1
Somnolence		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
Syncope		
subjects affected / exposed	5 / 230 (2.17%)	1 / 118 (0.85%)
occurrences (all)	6	1
Tremor		
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)
occurrences (all)	3	1
Viith Nerve Paralysis		

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Agitation		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
<b>Blood and lymphatic system disorders</b>		
Anaemia		
subjects affected / exposed	173 / 230 (75.22%)	91 / 118 (77.12%)
occurrences (all)	173	91
Aplastic Anaemia		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Coagulopathy		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Febrile Neutropenia		
subjects affected / exposed	2 / 230 (0.87%)	3 / 118 (2.54%)
occurrences (all)	2	3
Granulocytopenia		
subjects affected / exposed	13 / 230 (5.65%)	5 / 118 (4.24%)
occurrences (all)	59	8
Iron Deficiency Anaemia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Leukocytosis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	2	0
Leukopenia		
subjects affected / exposed	31 / 230 (13.48%)	12 / 118 (10.17%)
occurrences (all)	80	23
Lymphadenopathy		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Neutropenia		
subjects affected / exposed	69 / 230 (30.00%)	43 / 118 (36.44%)
occurrences (all)	163	93

Pancytopenia			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Thrombocytopenia			
subjects affected / exposed	38 / 230 (16.52%)	11 / 118 (9.32%)	
occurrences (all)	75	13	
Thrombocytosis			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Ear and labyrinth disorders			
Cerumen Impaction			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Ear Discomfort			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Ear Pain			
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences (all)	2	1	
Hypoacusis			
subjects affected / exposed	6 / 230 (2.61%)	3 / 118 (2.54%)	
occurrences (all)	6	3	
Neurosensory Hypoacusis			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Tinnitus			
subjects affected / exposed	19 / 230 (8.26%)	11 / 118 (9.32%)	
occurrences (all)	27	22	
Vertigo			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Vertigo Positional			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Eye disorders			

Blepharospasm		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Blindness Transient		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Conjunctivitis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Dry Eye		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
Eye Irritation		
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)
occurrences (all)	3	0
Eye Pain		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Eye Pruritus		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	2
Eyelid Oedema		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Eyes Sunken		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Lacrimation Increased		
subjects affected / exposed	6 / 230 (2.61%)	0 / 118 (0.00%)
occurrences (all)	8	0
Ocular Hyperaemia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Ocular Icterus		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0

Photophobia			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Photopsia			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Retinal Dystrophy			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Vision Blurred			
subjects affected / exposed	4 / 230 (1.74%)	1 / 118 (0.85%)	
occurrences (all)	5	3	
Visual Acuity Reduced			
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)	
occurrences (all)	3	1	
Visual Impairment			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Gastrointestinal disorders			
Abdominal Discomfort			
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)	
occurrences (all)	3	1	
Abdominal Distension			
subjects affected / exposed	19 / 230 (8.26%)	5 / 118 (4.24%)	
occurrences (all)	34	11	
Abdominal Mass			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Abdominal Pain			
subjects affected / exposed	44 / 230 (19.13%)	12 / 118 (10.17%)	
occurrences (all)	65	14	
Abdominal Pain Lower			
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences (all)	2	1	
Abdominal Pain Upper			

subjects affected / exposed	17 / 230 (7.39%)	11 / 118 (9.32%)
occurrences (all)	22	11
<b>Abdominal Tenderness</b>		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
<b>Abdominal Wall Mass</b>		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
<b>Anal Fissure</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Anal Haemorrhage</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Anal Pruritus</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Anorectal Discomfort</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Ascites</b>		
subjects affected / exposed	13 / 230 (5.65%)	9 / 118 (7.63%)
occurrences (all)	17	9
<b>Constipation</b>		
subjects affected / exposed	39 / 230 (16.96%)	17 / 118 (14.41%)
occurrences (all)	52	32
<b>Dental Caries</b>		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
<b>Diarrhoea</b>		
subjects affected / exposed	43 / 230 (18.70%)	23 / 118 (19.49%)
occurrences (all)	76	47
<b>Dry Mouth</b>		
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)
occurrences (all)	3	0
<b>Duodenal Ulcer Haemorrhage</b>		

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Dyspepsia		
subjects affected / exposed	8 / 230 (3.48%)	6 / 118 (5.08%)
occurrences (all)	8	7
Dysphagia		
subjects affected / exposed	10 / 230 (4.35%)	9 / 118 (7.63%)
occurrences (all)	12	14
Epigastric Discomfort		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Eructation		
subjects affected / exposed	0 / 230 (0.00%)	3 / 118 (2.54%)
occurrences (all)	0	3
Faeces Discoloured		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Flatulence		
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)
occurrences (all)	3	1
Gastric Haemorrhage		
subjects affected / exposed	3 / 230 (1.30%)	4 / 118 (3.39%)
occurrences (all)	3	5
Gastric Perforation		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
Gastric Stenosis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Gastritis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Gastrointestinal Haemorrhage		
subjects affected / exposed	3 / 230 (1.30%)	1 / 118 (0.85%)
occurrences (all)	3	1
Gastrointestinal Obstruction		

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Gastrointestinal Sounds Abnormal		
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)
occurrences (all)	3	0
Gastroesophageal Reflux Disease		
subjects affected / exposed	2 / 230 (0.87%)	2 / 118 (1.69%)
occurrences (all)	2	2
Haematemesis		
subjects affected / exposed	2 / 230 (0.87%)	2 / 118 (1.69%)
occurrences (all)	4	2
Haemorrhagic Ascites		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Haemorrhoids		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Hiatus Hernia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Intestinal Obstruction		
subjects affected / exposed	3 / 230 (1.30%)	2 / 118 (1.69%)
occurrences (all)	5	3
Large Intestinal Obstruction		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Lip Dry		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Melaena		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	4	0
Nausea		
subjects affected / exposed	125 / 230 (54.35%)	62 / 118 (52.54%)
occurrences (all)	277	132
Obstruction Gastric		

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Odynophagia</b>		
subjects affected / exposed	1 / 230 (0.43%)	3 / 118 (2.54%)
occurrences (all)	1	3
<b>Oesophageal Polyp</b>		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
<b>Oesophagitis</b>		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
<b>Oral Mucosal Eruption</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Pancreatitis Acute</b>		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
<b>Paraesthesia Oral</b>		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
<b>Periodontal Disease</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Proctalgia</b>		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
<b>Rectal Haemorrhage</b>		
subjects affected / exposed	0 / 230 (0.00%)	3 / 118 (2.54%)
occurrences (all)	0	3
<b>Reflux Gastritis</b>		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
<b>Regurgitation</b>		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
<b>Retching</b>		

subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences (all)	2	1	
Salivary Hypersecretion			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Sensitivity Of Teeth			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Stomatitis			
subjects affected / exposed	4 / 230 (1.74%)	18 / 118 (15.25%)	
occurrences (all)	4	36	
Tongue Discolouration			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Tooth Impacted			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Toothache			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Upper Gastrointestinal Haemorrhage			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	83 / 230 (36.09%)	35 / 118 (29.66%)	
occurrences (all)	147	63	
Hepatobiliary disorders			
Biliary Dilatation			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Cholecystitis Acute			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Hepatomegaly			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	

Hepatotoxicity			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	2	
Hyperbilirubinaemia			
subjects affected / exposed	7 / 230 (3.04%)	3 / 118 (2.54%)	
occurrences (all)	10	3	
Jaundice			
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)	
occurrences (all)	2	1	
Jaundice Cholestatic			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Portal Vein Phlebitis			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	2	
Skin and subcutaneous tissue disorders			
Alopecia			
subjects affected / exposed	7 / 230 (3.04%)	10 / 118 (8.47%)	
occurrences (all)	7	10	
Blister			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	2	
Cold Sweat			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Dermatitis Acneiform			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Dermatitis Allergic			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Dry Skin			
subjects affected / exposed	5 / 230 (2.17%)	4 / 118 (3.39%)	
occurrences (all)	7	4	
Erythema			

subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hyperhidrosis		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Ingrowing Nail		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Nail Discolouration		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Nail Disorder		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Night Sweats		
subjects affected / exposed	2 / 230 (0.87%)	2 / 118 (1.69%)
occurrences (all)	4	2
Onychalgia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Onychoclasia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Petechiae		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Pruritus		
subjects affected / exposed	1 / 230 (0.43%)	2 / 118 (1.69%)
occurrences (all)	1	2
Rash		
subjects affected / exposed	13 / 230 (5.65%)	6 / 118 (5.08%)
occurrences (all)	16	8
Rash Generalised		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Rash Maculo-Papular		

subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Rash Papular		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Skin Atrophy		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Skin Discolouration		
subjects affected / exposed	5 / 230 (2.17%)	0 / 118 (0.00%)
occurrences (all)	6	0
Skin Disorder		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Skin Hyperpigmentation		
subjects affected / exposed	4 / 230 (1.74%)	3 / 118 (2.54%)
occurrences (all)	4	3
Skin Lesion		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Skin Mass		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Skin Tightness		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Skin Toxicity		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Skin Ulcer		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Vascular Skin Disorder		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Vulvovaginal Pruritus		

subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Yellow Skin subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Renal and urinary disorders			
Bladder Discomfort subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Chromaturia subjects affected / exposed occurrences (all)	0 / 230 (0.00%) 0	1 / 118 (0.85%) 1	
Dysuria subjects affected / exposed occurrences (all)	4 / 230 (1.74%) 4	1 / 118 (0.85%) 1	
Haematuria subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	0 / 118 (0.00%) 0	
Hydronephrosis subjects affected / exposed occurrences (all)	3 / 230 (1.30%) 3	0 / 118 (0.00%) 0	
Pollakiuria subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	2 / 118 (1.69%) 2	
Renal Colic subjects affected / exposed occurrences (all)	1 / 230 (0.43%) 1	0 / 118 (0.00%) 0	
Renal Failure subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	1 / 118 (0.85%) 1	
Renal Failure Acute subjects affected / exposed occurrences (all)	5 / 230 (2.17%) 6	1 / 118 (0.85%) 1	
Renal Failure Chronic subjects affected / exposed occurrences (all)	2 / 230 (0.87%) 2	0 / 118 (0.00%) 0	

Renal Impairment		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Renal Vein Thrombosis		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Ureteric Obstruction		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Urinary Incontinence		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Urinary Retention		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Urinary Tract Obstruction		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Urine Flow Decreased		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Scrotal Oedema		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Vaginal Discharge		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Vulvovaginal Burning Sensation		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Vulvovaginal Discomfort		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Vulvovaginal Dryness		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0

Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	7 / 230 (3.04%)	0 / 118 (0.00%)	
occurrences (all)	8	0	
Back Pain			
subjects affected / exposed	16 / 230 (6.96%)	5 / 118 (4.24%)	
occurrences (all)	18	7	
Bone Pain			
subjects affected / exposed	4 / 230 (1.74%)	4 / 118 (3.39%)	
occurrences (all)	4	4	
Flank Pain			
subjects affected / exposed	3 / 230 (1.30%)	0 / 118 (0.00%)	
occurrences (all)	3	0	
Groin Pain			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Intervertebral Disc Disorder			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Joint Range Of Motion Decreased			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Lumbar Vertebral Fracture			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Muscle Spasms			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Muscle Tightness			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Muscular Weakness			

subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Musculoskeletal Chest Pain			
subjects affected / exposed	5 / 230 (2.17%)	0 / 118 (0.00%)	
occurrences (all)	5	0	
Musculoskeletal Pain			
subjects affected / exposed	3 / 230 (1.30%)	2 / 118 (1.69%)	
occurrences (all)	3	2	
Myalgia			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Neck Pain			
subjects affected / exposed	5 / 230 (2.17%)	0 / 118 (0.00%)	
occurrences (all)	5	0	
Osteoarthritis			
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)	
occurrences (all)	2	0	
Pain In Extremity			
subjects affected / exposed	11 / 230 (4.78%)	4 / 118 (3.39%)	
occurrences (all)	16	4	
Pain In Jaw			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Pelvic Floor Muscle Weakness			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Spinal Deformity			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Spinal Osteoarthritis			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Infections and infestations			
Abdominal Infection			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	

Biliary Tract Infection		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Bronchitis		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	2
Bronchopneumonia		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Candidiasis		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Cystitis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Device Related Infection		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Enteritis Infectious		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Enterocolitis Infectious		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Erysipelas		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Fungal Skin Infection		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Gastroenteritis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Herpes Zoster		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0

Hordeolum		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Impetigo		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Infection		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Influenza		
subjects affected / exposed	4 / 230 (1.74%)	2 / 118 (1.69%)
occurrences (all)	6	2
Lobar Pneumonia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Localised Infection		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Lower Respiratory Tract Infection		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Lung Infection		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Nail Infection		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Nasopharyngitis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Neutropenic Sepsis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Opportunistic Infection		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	2	0

Oral Candidiasis		
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)
occurrences (all)	1	1
Oropharyngeal Candidiasis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Otitis Externa		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Pneumonia		
subjects affected / exposed	5 / 230 (2.17%)	0 / 118 (0.00%)
occurrences (all)	6	0
Postoperative Wound Infection		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Pyelonephritis Acute		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Respiratory Tract Infection		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Respiratory Tract Infection Viral		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Sepsis		
subjects affected / exposed	2 / 230 (0.87%)	1 / 118 (0.85%)
occurrences (all)	2	1
Septic Shock		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Severe Acute Respiratory Syndrome		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Sinusitis		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0

Tonsillitis			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Tooth Infection			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Upper Respiratory Tract Infection			
subjects affected / exposed	4 / 230 (1.74%)	0 / 118 (0.00%)	
occurrences (all)	4	0	
Urinary Tract Infection			
subjects affected / exposed	7 / 230 (3.04%)	2 / 118 (1.69%)	
occurrences (all)	9	4	
Viral Infection			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Viral Upper Respiratory Tract Infection			
subjects affected / exposed	4 / 230 (1.74%)	2 / 118 (1.69%)	
occurrences (all)	4	2	
Vascular Pseudoaneurysm			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	
Metabolism and nutrition disorders			
Abnormal Loss Of Weight			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Alkalosis Hypochloreaemic			
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)	
occurrences (all)	0	1	
Cachexia			
subjects affected / exposed	1 / 230 (0.43%)	1 / 118 (0.85%)	
occurrences (all)	1	1	
Decreased Appetite			
subjects affected / exposed	96 / 230 (41.74%)	41 / 118 (34.75%)	
occurrences (all)	187	70	
Dehydration			

subjects affected / exposed	10 / 230 (4.35%)	5 / 118 (4.24%)
occurrences (all)	13	8
Diabetes Mellitus		
subjects affected / exposed	0 / 230 (0.00%)	1 / 118 (0.85%)
occurrences (all)	0	1
Hyperglycaemia		
subjects affected / exposed	5 / 230 (2.17%)	0 / 118 (0.00%)
occurrences (all)	5	0
Hyperkalaemia		
subjects affected / exposed	2 / 230 (0.87%)	4 / 118 (3.39%)
occurrences (all)	3	6
Hypermagnesaemia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hyperphosphataemia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hypertriglyceridaemia		
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)
occurrences (all)	1	0
Hypoalbuminaemia		
subjects affected / exposed	6 / 230 (2.61%)	5 / 118 (4.24%)
occurrences (all)	7	9
Hypocalcaemia		
subjects affected / exposed	6 / 230 (2.61%)	2 / 118 (1.69%)
occurrences (all)	8	2
Hypoglycaemia		
subjects affected / exposed	2 / 230 (0.87%)	0 / 118 (0.00%)
occurrences (all)	2	0
Hypokalaemia		
subjects affected / exposed	6 / 230 (2.61%)	10 / 118 (8.47%)
occurrences (all)	6	19
Hypomagnesaemia		
subjects affected / exposed	24 / 230 (10.43%)	9 / 118 (7.63%)
occurrences (all)	31	11
Hyponatraemia		

subjects affected / exposed	5 / 230 (2.17%)	8 / 118 (6.78%)	
occurrences (all)	7	14	
Hypophosphataemia			
subjects affected / exposed	2 / 230 (0.87%)	2 / 118 (1.69%)	
occurrences (all)	2	2	
Podagra			
subjects affected / exposed	1 / 230 (0.43%)	0 / 118 (0.00%)	
occurrences (all)	1	0	

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
06 July 2010	<ul style="list-style-type: none"><li>- Clarified the indication in the Protocol Synopsis.</li><li>- Revised Inclusion Criterion #2 revised to indicate that histologic type will be confirmed by Central Pathology Review, and that patients may only be randomized after central pathology review has confirmed histologic type.</li><li>- Increased the baseline period during which histological confirmation of metastatic diffuse gastric cancer could be obtained from the central pathology laboratory from Day -28 through Day -4 to Day -28 through Day 1 prior to randomization.</li><li>- Clarified that additional blood samples for hematology testing (Days 8 and 22 for S-1 group; Day 8 for 5-FU group) are to be obtained during Cycles 1 through 8 or through the last cycle in which cisplatin is administered</li><li>- Changed the timing of healthcare utilization assessment from Day 1 of each cycle to the end of the rest period of each cycle.</li><li>- Modified text for consistency with respect to the timing of survival follow-up visits (every 8 weeks instead of every 2 months).</li><li>- Removed the requirement to assess C-reactive protein.</li><li>- Clarified the criterion for when an End-of-Treatment Visit is and is not required.</li></ul>
12 December 2011	<ul style="list-style-type: none"><li>- Revised Exclusion Criterion #1, which specified that all patients with only non-measurable lesions should be excluded was modified to allow patients with some types of non-measurable disease entry into the study</li><li>- Increased the Baseline period during which CT scans for tumor measurement could be obtained from Day -28 through Day -4 to within 28 days prior to randomization.</li><li>- Clarified Inclusion Criterion #2, which specified that patients should have unresectable tumors, to indicate that this applied only at the time of screening for study (i.e., patient may have had resectable tumor in the past).</li><li>- Clarified Inclusion Criterion #5, which specified that patients should be able to take medications orally, to indicate that capsule contents should not be crushed or removed and given through a feeding tube.</li><li>- Revised Inclusion Criterion #12 to clarify birth control requirements for both females and males.</li><li>- Clarified, the dosing of 5-FU on Days 1 through 5 in Section 7.2.1.</li><li>- Added the following drugs to the list of prohibited medications: nitroimidazoles, including metronidazole and misonidazole, methotrexate, and clozapine.</li></ul>
04 February 2014	<ul style="list-style-type: none"><li>- No patients would be randomized after 28 February 2014.</li><li>- All patients would continue on study medication until any of the discontinuation criteria is met.</li><li>- Patients currently enrolled would be followed until 6 months after randomization of the last patient. This allowed for an overall median follow-up time of approximately 22 months, which was at least twice as long as the target treatment median of 10 months. In addition, a 6- month minimum survival follow-up for all patients approximated the hypothesized control OS median.</li><li>- The institutional site's standard of care procedures would be followed, and study medication dosing, SAEs, and AEs related to medication discontinuation would be collected while the patient remained on treatment. Concomitant medications would only be reported if they were related to an SAE or AE related to medication discontinuation. Non-serious AEs leading to study drug discontinuation would be collected. These patients would be followed for 30 days after discontinuation from study treatment or the initiation of new anticancer therapy, whichever was earlier, after which there would be no follow-up.</li></ul>
03 May 2014	Changed the Sponsor's name as of 01April 2014 from Taiho Pharmaceutical USA, Inc. (TPUI) to Taiho Oncology, Inc., and updated to add an additional Medical Monitor name and contact information for the study.

---

Notes:

---

### **Interruptions (globally)**

Were there any global interruptions to the trial? No

### **Limitations and caveats**

Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.

As of 28 February 2014, the study was closed to slow accrual of enrollment. The decision was based on significant changes in the investigational and clinical practice landscape of frontline advanced gastric cancer (AGC).

Notes: